Occlutech said today that its eponymous atrial flow regulator device received CE Mark approval in the European market. The Occlutech AFR is an intra-atrial shunt designed be placed between the left and right atria to treat heart failure symptoms by decompressing abnormal intra-atrial pressure. In a release, the Germany-based company said malfunction of the left […]
Occlutech GmbH
Occlutech recalls cardiac implant on dislodgement risk
Structural heart disease implant developer Occlutech said it’s recalling some of its Occlutech left atrial appendix occluders over risks of dislocation of the device both during and post-procedure. The Occlutech LAA occluder is designed for the minimally invasive closure of the LAA to reduce the risk of stroke in patients with atrial fibrillation. The device consists of a […]
Occlutech wins CE Mark for LAA occluder
Structural heart disease implant developer Occlutech said today it won CE Mark approval in the European Union for its Left Atrial Appendix occluder device designed for the minimally invasive closure of the LAA to reduce the risk of stroke in patients with atrial fibrillation. The Occlutech LAA occluder device consists of a flexible nitinol wire mesh and […]
Occlutech wins CE Mark for VSD closure device
Structural heart disease implant developer Occlutech said today it won CE Mark approval in the European Union for its ventricle septal defect closure device. The occluding device consists of a flexible nitinol wire mesh, and is indicated for minimally invasive closure of VSDs, the company said. “We are extremely pleased to be able to provide patients and […]
Michigan judge shoots down settlement alleged by Biomet in poaching spat with Stryker | Medtech legal news for the week of July 28, 2014
Occlutech claims another win over St. Jude Medical
TCT 2013: Docs trade barbs over LAA closure
St. Jude Medical’s Amulet LAA occluder
Occlutech claims win in Dutch legal war with St. Jude Medical | Legal News
Occlutech GmbH is claiming victory in a legal battle with St. Jude Medical (NYSE:STJ) over structural heart implants, saying Holland’s Supreme Court upheld an earlier ruling in Occlutech’s favor.
Occlutech claims another win in legal battle with St. Jude Medical
Occlutech GmbH notched a win in its long-running patent war with St. Jude Medical (NYSE:STJ) over structural heart implants, saying an Italian court ruled that it doesn’t infringe a portion of a St. Jude patent.
St. Jude inherited the case, involving intravascular occlusion devices, after it acquired AGA Medical for more than $1 billion last year.
Occlutech CEO on St. Jude patent spat, FDA’s new 510(k) clearance process, Covidien moves manufacturing to Thailand | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Occlutech CEO: St. Jude’s patent suit against me “amazing and quite shocking” | Legal News
A patent spat between St. Jude Medical (NYSE:STJ) and Occlutech GmbH that morphed into a personal lawsuit against Occlutech CEO Tor Peters was dismissed by a German court, prompting Peters to call the suit "amazing and quite shocking."
St. Jude inherited the case, involving intravascular occlusion devices, after it acquired AGA Medical for more than $1 billion last year.
